CLOS
ARCT icon

Compagnie Lombard Odier SCmA’s Arcturus Therapeutics ARCT Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,000
Closed -$111K – 425
2025
Q3 		$111K Buy
+6,000
New +$96.4K ﹤0.01% 292

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Compagnie Lombard Odier SCmA's ARCT Position: Q4 2025 in Review

Compagnie Lombard Odier SCmA sold out of Arcturus Therapeutics (ARCT) in Q4 2025, closing a stake of 6,000 shares — an estimated $111K sold.

Compagnie Lombard Odier SCmA first reported a position in ARCT in Q3 2025 and held it in 1 quarter. The position peaked at $111K in Q3 2025. 120 funds tracked by Wall St. Rank hold ARCT as of Q4 2025.

  • Compagnie Lombard Odier SCmA reported no remaining Arcturus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 6,000 Arcturus Therapeutics shares in Q4 2025, an estimated $111K.
  • Compagnie Lombard Odier SCmA first reported a position in Arcturus Therapeutics in Q3 2025 and held it in 1 quarter.
  • Compagnie Lombard Odier SCmA's Arcturus Therapeutics position peaked at $111K in Q3 2025.
  • 120 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2025.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q4 2025, filed 16 Jan 2026.